Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Sarcoma 10Neoplasms 4Neoplasm Metastasis 2Leiomyosarcoma 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma 1Lung Neoplasms 1Liposarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Carboplatin 339Cisplatin 238Paclitaxel 203Radiotherapy 194Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 140Erlotinib Hydrochloride 107Etoposide 98Magnetic Resonance Spectroscopy 92Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 71durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49Irinotecan 42atezolizumab 41Topotecan 39Radiation 39Biopsy 39Cyclophosphamide 38Standard of Care 37Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × olaratumab × Clear all
NCT00918203 2019-01-10

A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 2 Completed
137 enrolled 23 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡